Sažetak
Background: Patients with pancreatitis may be at increased risk of cardiovascular disease (CVD), but the biochemical mechanisms underlying this risk are not fully defined. Inflammatory biomarkers may provide valuable prognostic information.
Methods: We retrospectively analyzed 180 patients with pancreatitis (Jan 2021–Dec 2023). Serum levels of interleukin-8 (IL-8), procalcitonin (PCT), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) were quantified using enzyme-linked immunosorbent assay (ELISA) and routine laboratory tests. Logistic regression was applied to identify independent biochemical predictors of CVD, and a risk prediction model was developed and validated using ROC curve analysis.
Results: IL-8, PCT, CRP, and age emerged as independent predictors of CVD occurrence in pancreatitis patients (all P<0.05). The biochemical prediction model demonstrated high accuracy, with an AUC of 0.893 in the training set and 0.978 in the validation set. Sensitivity and specificity exceeded 85% across datasets.
Conclusion: This study highlights the clinical and laboratory significance of inflammatory biomarkers in pancreatitis. The proposed biochemical model provides a reliable tool for predicting cardiovascular risk and may contribute to improved laboratory-guided risk assessment and patient management.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.